866-997-4948(US-Canada Toll Free)

Galvus (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jul 2013

Category :

Metabolic Disorders

No. of Pages : 48 Pages


GlobalData has released its new report, Galvus (Type 2 Diabetes) Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Galvus (vildagliptin) was developed by Novartis and has been approved for use in Europe since 2008, and in several countries outside of the US; however, the FDA rejected it, demanding additional clinical data. If it had not been rejected by the FDA, it would have launched in direct competition to Mercks Januvia.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Galvus including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Galvus for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Galvus performance
  • Obtain sales forecast for Galvus from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)
Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10

3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16

4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19

5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26

6 Galvus (vildagliptin) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Safety 30
6.4 SWOT Analysis 32
6.5 Forecast 32

7 Appendix 34
7.1 Bibliography 34
7.2 Abbreviations 38
7.3 Methodology 39
7.4 Forecasting Methodology 39
7.4.1 Diagnosed Type 2 Patients 39
7.4.2 Percent Drug-Treated Patients 40
7.4.3 Drugs Included in Each Therapeutic Class 40
7.4.4 Launch and Patent Expiry Dates 41
7.4.5 General Pricing Assumptions 41
7.4.6 Individual Drug Assumptions 42
7.4.7 Generic Erosion 42
7.5 Physicians and Specialists Included in this Study 43
7.6 About the Authors 45
7.6.1 Analyst II - CVMD 45
7.6.2 Therapy Director - CVMD and Infectious Disease 45
7.6.3 Global Head of Healthcare 46
7.7 About GlobalData 47
7.8 Disclaimer 47

List of Table


Table 1: Symptoms of Type 2 Diabetes 17
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 18
Table 3: Treatment Guidelines for Type 2 Diabetes 20
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 23
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 27
Table 6: Product Profile - Galvus 29
Table 7: Galvus SWOT Analysis, 2012 32
Table 8: Global Sales Forecasts ($m) for Galvus and Eucreas, 2012-2022 33
Table 9: Key Launch Dates 41
Table 10: Key Patent Expiries 41
Table 11: Number of High-Prescribing Physicians Surveyed 44

List of Chart


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *